- What the Market Looks Like?
Market growth can primarily be attributed to the widespread adoption of wound care biologics for the treatment of ulcers and burn injuries in developed countries and the high incidence rate of diabetic foot ulcers.
What the Market Looks Like?
The global Wound Care Biologics Market is expected to reach USD 2.26 Billion by 2023 from USD 1.42 Billion in 2018, at a CAGR of 9.8%. North America is expected to command the largest share of the market.
Market growth is mainly driven by factors such as the increasing incidence of diabetic foot ulcers, increasing geriatric population, and increasing burn injuries globally. On the other hand, the high cost of wound care biologics and the higher rejection rate associated with skin grafts & substitutes will restrain the growth of this market.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=259878425
The global market is segmented on the basis of product, wound type, end user, and region. By product, the market segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is estimated to account for the largest share of the market in 2018. The rising incidence of hard-to-heal wounds and their growing adoption (due to their high efficacy) are driving the growth of this product segment.
The biological skin substitutes segment is further categorized into human donor tissue-derived products, acellular animal-derived products, and biosynthetic products.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America is expected to command the largest share of the market. The large share of this segment can primarily be attributed to the high presence of key players in this region, the availability of a variety of wound biologics products, and the high prevalence of diabetic foot ulcers this region.
Read more about Global Surgical & Traumatic Wounds Market@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=259878425
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.